Early cytomegalovirus infections following allogeneic stem cell transplantation: a comparison between non-malignant and malignant haematological disorders

References

• Junghanss C, Boeckh M, Carter RA et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative com-pared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978–1985.
   PubMed Web of Science ®Google Scholar
• Oh Si, Lee KH, Lee JH et al. The risk of cytomegalovirus infectionin non-myeloablative peripheral stem cell transplantation com-pared with conventional bone marrow transplantation. J Korean Med Sci 2004; 19: 172–176.
   PubMed Web of Science ®Google Scholar
• Walker CM, van Bunk JA, de For TE, Weisdorf DJ. Cytomegalovirus infection after allogeneic transplantation: com-parison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant 2007; 13: 1106–1115.
   PubMed Web of Science ®Google Scholar
• Parody R, Martino R, Rovira M. Severe infections after unrelateddonor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant 2006; 12: 734–748.
   PubMed Web of Science ®Google Scholar
• Marsh JC, Ball SE, Darbyshire P et al. British Committee for Standards in Haematology (BCSH) General Haematology Task Force. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 2003; 123: 782–801.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.
   PubMed Web of Science ®Google Scholar
• Lee Si, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215–233.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirusinfection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094–1097.
   PubMed Web of Science ®Google Scholar
• Schaade L, Kockelkorn P, Ritter K, Kleines M. Detection of cytomegalovirus DNA in human specimens by LightCycler PCR. J Clin Microbiol 2000; 38: 4006–4009.
   PubMed Web of Science ®Google Scholar
• Falcao RP, Voltarelli JC, Bottura C. Some immunological studies in aplastic anaemia. J Clin Lab Immunol 1983; 10: 25–28.
   PubMedGoogle Scholar
• Scheinberg P, Fischer SH, Li L et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007; 109: 3219–3224.
   PubMed Web of Science ®Google Scholar
• Ozdemir E, Saliba RM, Champlin RE et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007; 40: 125–136.
   PubMed Web of Science ®Google Scholar
• van Bunk JA, Carter SL, Freifeld AG et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complica-tions in patients treated with T cell depletion versus immunosup-pressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 1487–1498.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Perez-Bercoff L, Jonsson J et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006; 91: 78–83.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nichols WG. The impact of cytomegalovirus serostatusof donor and recipient before hematopoietic stem cell transplanta-tion in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003–2008.
   PubMed Web of Science ®Google Scholar
• Yoon HS, Lee JH, Choi ES et al. Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors. Pediatr Transplant 2009; 13: 898–905.
   PubMed Web of Science ®Google Scholar
• Kroger N, Zabelina T, Kruger W et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretrans-plant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 2001; 113: 1060–1071.
   PubMed Web of Science ®Google Scholar
• Meijer E, Dekker AW, Rozenberg-Arska M, Weersink AJ, Verdonck LF. Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clin Infect Dis 2002; 35: 703–712.
   PubMed Web of Science ®Google Scholar
• Miller W, Flynn P, McCullough J et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986; 67: 1162–1167.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543–558.
   PubMed Web of Science ®Google Scholar
• Buyck HC, Ball S, Junagade P, Marsh J, Chakrabarti S. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant 2009; 43: 813–816.
   PubMed Web of Science ®Google Scholar
• Calistri E, Tiribelli M, Battista M et al. Epstein—Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia. Am J Hematol 2006; 81: 355–357.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell trans-plantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357–4363.
   PubMed Web of Science ®Google Scholar
• Asano-Mori Y, Kanda Y, Oshima K et al. Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplan-tation. Int J Hematol 2008; 87: 310–318.
   PubMed Web of Science ®Google Scholar
• Dodero A, Carrabba M, Milani R, Rizzo E, Raganato A, Montefusco V. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol 2005; 33: 920–927.
   PubMed Web of Science ®Google Scholar
• Cheung WW, Tse E, Leung AY, Yuen KY, Kwong YL. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab. Am J Hematol 2007; 82:108–111.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102: 4255–4260.
   PubMed Web of Science ®Google Scholar